CDMOs offering Upstream Processing with Biologics (Other)
34 published
34 published CDMOs match Upstream Processing and Biologics (Other).
Locations in this set include United States, China, United Kingdom, Germany, Japan, and Switzerland.
Capabilities that show up most often in this set: Downstream Processing, Process Development, CMC Analytical Development, Recombinant Protein Manufacturing, and Cell-Line Development.
Matching companies
KBI Biopharma, Inc.Global CDMO offering cell line development, process and analytical development, formulation development, and clinical and commercial manufacturing for mammalian and microbial biologics.
Lonza Cell & Gene TechnologiesLonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
Northway BiotechEnd-to-end CDMO specializing in protein-based biologics and gene therapies, with 20+ years of expertise and cGMP facilities in Lithuania and Massachusetts supporting development from preclinical to commercial stages.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Rezon BioEuropean biologics CDMO offering end-to-end development and manufacturing across two GMP-certified sites in Poland, with capabilities from cell line development to commercial-scale production.
Richter BioLogicsGermany-based CDMO specializing in GMP-compliant microbial production of recombinant proteins, peptides, plasmid DNA, and bacterial vaccines with bioreactor capacity up to 1,500 litres and regulatory clearance from FDA, EMA, ANVISA, PMDA, and MFDS.
Rodon BiologicsRodon Biologics is a biotech CRO/CDMO with over 20 years of activity. It offers protein engineering, recombinant protein production, cell line and process development, manufacturing, and analytical and stability testing services for biologics.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Sophia CDMOEuropean CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
ValidogenVALIDOGEN provides Pichia pastoris strain development and fermentation process development services for recombinant protein manufacturing, with proven scale-up to 200,000 L and titers up to 45 g/L.
WuXi BiologicsGlobal biologic CDMO offering end-to-end solutions from discovery to commercialization.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Markdown mirror: /explore/upstream-processing/biologics-other.md